TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00625248

Intervention type: DRUG
Intervention: Antithrombotics
Description: With or without or discontinuted use of Antithrombotics

Intervention type: DRUG
Intervention: Antithrombotics
Description: With or without or discontinuted use of Antithrombotics

Intervention type: DRUG
Intervention: Antithrombotics
Description: With or without or discontinuted use of Antithrombotics
Study: NCT00735020

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted Influenza Vaccine
Description: 1 dose of Adjuvanted Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccine
Description: 1 dose of Influenza Vaccine
Study: NCT03361280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta blocker
Description: Beta blockers are administered as described in arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta blocker
Description: Beta blockers are administered as described in arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta blocker
Description: Beta blockers are administered as described in arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta blocker
Description: Beta blockers are administered as described in arms.
Study: NCT03624348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: meditation
Description: 10 minute per day, 8 week digital meditation
Study: NCT01352117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz/emtricitabine/tenofovir disoproxil fumarate
Description: 600 mg efavirenz/200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally at night

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz/emtricitabine/tenofovir disoproxil fumarate
Description: 600 mg efavirenz/200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally at night

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: 50 mg taken orally daily from days 1-7 of each 2-week cycle. For participants without PR or CR after two cycles of therapy and no toxicity greater than Grade 2, the dose of ET was escalated to 100 mg/day orally, days 1-7, every 2 weeks. A cycle could be delayed for a maximum of 14 days. ET could not be initiated prior to 7 days after the last dose in previous cycle. ET could be administered up to a maximum of eight cycles (2 cycles during dose titration and 6 cycles at maximum dose). Participants who could not tolerate escalation of the ET dose to 100 mg/day were treated for a maximum of six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 50 mg taken orally daily from days 1-7 of each 2-week cycle. For participants without PR or CR after two cycles of therapy and no toxicity greater than Grade 2, the dose of ET was escalated to 100 mg/day orally, days 1-7, every 2 weeks. A cycle could be delayed for a maximum of 14 days. ET could not be initiated prior to 7 days after the last dose in previous cycle. ET could be administered up to a maximum of eight cycles (2 cycles during dose titration and 6 cycles at maximum dose). Participants who could not tolerate escalation of the ET dose to 100 mg/day were treated for a maximum of six cycles.
Study: NCT00633477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resatorvid
Description: Resatorvid 1.2 mg/kg emulsion, injection for 30 minutes and resatorvid 2.4 mg/kg per-day emulsion, injection, continuous infusion for 96 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Resatorvid placebo-matching emulsion, injection for 30 minutes and resatorvid placebo-matching emulsion, injection, continuous infusion for 96 hours.
Study: NCT04532268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humanized CD19 CAR-T cells
Description: Each subject receive humanized CD19 CAR T-cells by intravenous infusion
Study: NCT03121313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tegafur-uracil
Study: NCT03897426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet - Remote Coaching using a Mobile App
Description: Patients randomized to the intervention arm will be then given an instruction booklet on using Mobile App, directed to a website for additional instruction on its use, and have the app set up to establish connectivity to the RD.
Study: NCT04002960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00036
Description: Noninvasive regional oximeter
Study: NCT01288573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: 160 μg/kg subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: 240 μg/kg subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: 320 μg/kg subcutaneous (SC) injection
Study: NCT00708292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT01649895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: Predicted to enhance the effects of exposure in internet-based cognitive-behaviour therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills as adjunct to internet-based cognitive-behaviour therapy
Study: NCT00179621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide 5 mg
Description: Lenalidomide 5 mg daily 28/28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg
Description: Lenalidomide 10 mg daily 21/28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, matching to active study drug arms
Study: NCT01777308

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal conjugate vaccine GSK134612
Description: Single dose to be administrated intramuscularly in the deltoid of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal conjugate vaccine GSK134612
Description: Single dose to be administrated intramuscularly in the deltoid of the non-dominant arm
Study: NCT03567564

Intervention type: DIAGNOSTIC_TEST
Intervention: Abdominal muscles ultrasound
Description: Abdominal muscles ultrasound during a spontaneous breathing trial using the M-mode to calculate the thickening fraction of the anterior and lateral abdominal muscles under multiple circumstances (tasks performed by the patients)
Study: NCT03363737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transtheoretical Model
Description: Exposure to content on Facebook, either daily (dynamic) or just at one time period (static).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transtheoretical Model
Description: Exposure to content on Facebook, either daily (dynamic) or just at one time period (static).
Study: NCT02718079

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma Exchange

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Management of cerebral edema/intracranial hypertension:

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Management of cerebral edema/intracranial hypertension:

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transfer to Intensive Care Unit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transfer to Intensive Care Unit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic Antibiotics
Study: NCT00417261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATF936

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ATF936
Study: NCT02718079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic Antibiotics

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intubation of trachea

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intubation of trachea

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volume Replacement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volume Replacement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressor Support

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressor Support

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl-L-cysteine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl-L-cysteine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Correction of metabolic parameters

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correction of metabolic parameters

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Correction of nutrition

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Correction of nutrition
Study: NCT03896139

Intervention type: DRUG
Intervention: Kinase inhibitor
Description: Patients treated with kinase inhibitors for cancer or other conditions

Intervention type: DRUG
Intervention: Kinase inhibitor
Description: Patients treated with kinase inhibitors for cancer or other conditions
Study: NCT03772899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplantation
Description: All patients in this trial will receive FMT at least one week prior to treatment with approved immunotherapy (either pembrolizumab or nivolumab). Samples for FMT are sourced at and by the microbiology group under the supervision of Dr. Silverman at St Joseph's Hospital. Donor screening procedures are described in appendix 4. Transplant will be from one single donor for all participants unless Dr. Silverman's lab considers the need for more than one donor based on availability of donors. There will be no mixture of donor samples.~Donor samples are manufactured into capsules according to Kao et al, 2017.
Study: NCT00644423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty Acid
Description: One capsule three times per day x 1 day (325mg EPA/225mg docosahexaenoic acid (DHA) tid) Two capsules three times per day x 1 day (650mg EPA/450mg DHA tid) Three capsules three times per day thereafter (975mg EPA/675mg DHA tid)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT00781768

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard PO (Zofran + Dexamethason)
Description: Dexamethasone 10 mg (dose blinded) in 50 ml D5W IVPB over 15 minutes daily + ondansetron 8mg PO q 8 hours - repeated qd of the preparative regimen and for 1 day after completion. A placebo capsule will be given daily on each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant (MK-869) + Standard PO
Description: Dexamethasone 7.5 mg (dose blinded) in 50 ml D5W IVPB over 15 min daily + ondansetron 8mg PO q 8 hours - repeated QD of the preparative regimen and for 1 day after completion. Aprepitant 125mg PO \[blinded\] will be given a minimum of 30 minutes prior to the preparative regimen on day 1. MK-Aprepitant 80mg PO \[blinded\] will be given will be given approximately 24 hours later starting on day 2 then each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
Study: NCT01395797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIO
Description: 0, 15, and 45 mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIO
Description: 0, 15, and 45 mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIO
Description: 0, 15, and 45 mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIO
Description: 0, 15, and 45 mg per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PIO
Description: 0, 15, and 45 mg per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01500590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system blockers
Description: ramipril 2.5mg to 10mg once daily if patient experience cough, we will use irbesartan 150 mg to 300mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-renin angiotensin system blockers
Description: amlodipine 2.5 to 10 mg once daily nifedipine retard 20mg to 40mg twice daily indapamide 2.5mg once daily metoprolol 25mg to 100mg daily methyldopa 125 mg to 500mg twice daily
Study: NCT02025686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen
Description: Subjects will breathe oxygen (FIO2 = 1.0) at 2.4 ATA in a hyperbaric chamber after the tonic heat stimulations. The duration of oxygen exposure is 90 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal ambient conditions
Description: Normal ambient conditions (1 ATA, FIO2 = 0.21)
Study: NCT03744910

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Clazakizumab
Description: Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline solution
Description: Normal saline
Study: NCT00500617

Intervention type: DIAGNOSTIC_TEST
Intervention: Corus CAD (ASGES)
Description: Age/Sex/Gene Expression Score - ASGES

Intervention type: DIAGNOSTIC_TEST
Intervention: Corus CAD (ASGES)
Description: Age/Sex/Gene Expression Score - ASGES

Intervention type: DIAGNOSTIC_TEST
Intervention: Corus CAD (ASGES)
Description: Age/Sex/Gene Expression Score - ASGES

Intervention type: DIAGNOSTIC_TEST
Intervention: Corus CAD (ASGES)
Description: Age/Sex/Gene Expression Score - ASGES
Study: NCT01647789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFG920
Study: NCT03744312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-ER176
Description: 11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease.
Study: NCT00417261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXT914

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AXT914
Study: NCT03284047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Participants will be randomized to one of three botulinum toxin type A doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Participants will be randomized to one of three botulinum toxin type A doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Participants will be randomized to one of three botulinum toxin type A doses.
Study: NCT03744312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 11C-ER176
Description: 11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetaben
Description: Florbetaben sticks to amyloid plaques, which are in the brain in Alzheimer's disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Florbetaben
Description: Florbetaben sticks to amyloid plaques, which are in the brain in Alzheimer's disease.
Study: NCT01893463

Intervention type: DEVICE
Intervention: iTClamp50
Study: NCT02686372

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCR-T
Description: Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: No intervention and TCR-T (at crossover)
Description: Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
Study: NCT04432935

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Lactoferrin
Description: Lactoferrin is a nutritional supplement which was first discovered in bovine milk which was later isolated in human milk as the second most abundant protein; with high levels found in colostrum. The use of bovine Lactoferrin in children is generally recognized as safe by the US Food and Drug Administration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Glucon D
Description: This group will be given 100mg Glucon-D (99.4% glucose) which will be similar in shape, color to the bLF.
Study: NCT03096834

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG334 (70 mg) Pre-Filled Syringe (PFS)
Description: Two injections of AMG 334 70 mg (equaling 140 mg total dose) will be administered via subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG334 (70 mg) Pre-Filled Syringe (PFS)
Description: Two injections of AMG 334 70 mg (equaling 140 mg total dose) will be administered via subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG334 (70 mg) Pre-Filled Syringe (PFS)
Description: Two injections of AMG 334 70 mg (equaling 140 mg total dose) will be administered via subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pre-Filled Syringe (PFS)
Description: Subcutaneous injection of matching placebo
Study: NCT00246519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: atenolol 50 or 100 mg hydrochlorothiazide 12.5 or 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: atenolol 50 mg, then 100 mg if BP \< 120/70, then add HCTZ 12.5 mg if BP \< 120/70, then HCTZ 25 mg if BP \< 120/70
Study: NCT02374697

Intervention type: DEVICE
Intervention: During tele-expertise
Study: NCT03170349

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitral Valve Repair
Description: Minimal Invasive Transcatheter Mitral Valve Repair
Study: NCT00002649

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo autologous peripheral blood stem cell transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support
Description: Undergo bone marrow ablation with stem cell support
Study: NCT04017221

Intervention type: DRUG
Intervention: Sodium-glucose cotransporter 2 (SGLT2) inhibitors
Description: Current exposure to SGLT2 will be defined as a prescription for a SGLT2 inhibitor (canagliflozin, dapagliflozin, empagliflozin) alone or in combination with other antidiabetic drugs, excluding DPP-4 inhibitors and insulin.

Intervention type: DRUG
Intervention: Dipeptidyl peptidase-4 (DPP-4) inhibitors
Description: Current exposure to DPP-4 will be defined as a prescription for a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with other antidiabetic drugs, excluding SGLT2 inhibitors and insulin.

Intervention type: DRUG
Intervention: Other treatment combinations
Description: Current exposure to other treatment combinations will be defined as a prescription of other antidiabetic drugs (metformin, sulfonylureas, thiazolidinediones, GLP-1 receptor agonists, alpha-glucosidase inhibitors, meglitinides, insulin, or combinations of these drugs), current use of insulin (alone or combination with other antidiabetic drugs), and non-current use of antidiabetic drugs.
Study: NCT04045535

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Program
Description: Usual Care and a nurse-led physical activity program once a week for 8 weeks. Each session last for 60 minutes, 15 for warming-up and 45 for different exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual clinical care based on current clinical practice guidelines.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual clinical care based on current clinical practice guidelines.
Study: NCT03338777

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Suicide plus immunogene therapy
Description: 1. Intra and peritumoral infiltrates with multiple injections of 0.1 ml/cm2 or 0.2 ml/cm3 of lipoplexes bearing the HSVtk suicide gene (1: 1; 1 mg/ml, according to tumor size), co-administered with GCV (12.5 mg/ml). Patients start with a minimum of 0.5 ml and at the 3rd week, the maximum dose is scaled according to the tumor size up to 2 ml maximum.~2. Treated simultaneously with a subcutaneous vaccine produced with:~   * Formolized allogeneic tumor extracts and,~  * Lipoplexes carrying hIL-2 and hGM-CSF genes (0.5 mg each).
Study: NCT00717574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane group
Description: Addition of 60% nitrous oxide for 20 minutes duration, then back to 1:1 oxygen/air mixture.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol group
Description: Addition of 60% nitrous oxide for 20 minutes duration, then back to 1:1 oxygen/air mixture.
Study: NCT00982293

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resonator device
Description: Low level electromagnetic fields for whole body immersion, 3 times weekly for 13 weeks (39) sessions of approximately 11/2 hours each.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Resonator device - sham
Description: Treatment, 3 times weekly for 13 weeks (39) sessions - device will not be on
Study: NCT00704015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Description: Nurses, specifically trained for smoking cession program, contacted the patients at the orthopedic wards and initiated the intervention (stop smoking) within 1-2 days after acute hospitalization. The intervention included one or two personal meetings and weekly phone contacts during 6 weeks with a trained nurse. A phone number to a non-smoking hotline was provided for all patients. The patients were continuously encouraged not to smoke and free nicotine substitution (Nicorette®) was offered those who needed it. No other drug therapy was used.